Mode
Text Size
Log in / Sign up
N/A Completed N=47 Supportive Care

Evaluation of an Ascensia Diabetes Care Blood Glucose Meter and App System

Source: ClinicalTrials.gov NCT03165110 ↗
Enrolled (actual)
47
Serious AEs
0.0%
Results posted
Jun 2019
Primary outcomePrimary: Percent of Responses From Persons With Diabetes That 'Strongly Agree' or 'Agree' or 'Neither Agree Nor Disagree' With Questionnaire Statements Regarding Success With Syncing the Reading on the Onyx Glucose Meter and App. — 89.13 percentage of participants

Summary

The purpose of this study is to assess the utility of the Contour Diabetes App 2.0 when used with the Contour Next One meter (the Onyx system).

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent of Responses From Persons With Diabetes That 'Strongly Agree' or 'Agree' or 'Neither Agree Nor Disagree' With Questionnaire Statements Regarding Success With Syncing the Reading on the Onyx Glucose Meter and App.
89.13 —
PRIMARY
Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or 'Neither Agree Nor Disagree' With Questionnaire Statements Regarding Success in Accessing and Using Smart Reminders Feature in the Onyx App System
26; 20 —
PRIMARY
Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neither Agree Nor Disagree' With Questionnaire Statements Regarding Success at Accessing the Expanded Graph and My Readings View in the Onyx App System
46 —
PRIMARY
Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neither Agree Nor Disagree' With Questionnaire Statements Regarding Success in Interpreting the Expanded Graph and My Readings View in the Onyx App System
45 —
SECONDARY
Change in HbA1c% From Study Start to End of Study
7.7273003; 7.6993933 —
SECONDARY
Change in Fructosamine (µmol/L) From Study Start to End of Study
332.8; 322.7 —
SECONDARY
Average Change in Subject Body Weight From Study Start to End of Study
194.4; 193.8 —
SECONDARY
Average Change in Subject BMI From Study Start to End of Study
29.723913; 29.636304 —
SECONDARY
Average Change in Total Daily Insulin Dose From Study Start to End of Study
76.869565; 78.326087 —

Eligibility Criteria

Inclusion Criteria

  • Be aged 18-75 years, male or female
  • Read and understand English
  • Have diagnosis of type 1 (goal is 40% to 70%) or insulin-using type 2 diabetes for at least 6 months
  • Be taking multiple daily insulin injections (MDI) of at least two pre-meal bolus insulin injections daily or using an insulin pump (Goal is not more than 30% of subjects using insulin pump therapy)
  • Performing self-monitoring of blood glucose at home at least twice daily
  • Have an iOS mobile device or Android mobile device with Bluetooth capability iOS device: iPod, iPad, or iPhone 5 or later version with iOS 9.x or 10.x software Android: smart phone, software version 6.x. Bluetooth: software version 4.0 or higher
  • Agree NOT to update the software on their mobile device until after the study is concluded, as follows:
  • No updates of Android device to upcoming Android version 7 (Nougat)
  • Be willing to utilize the Contour Next One meter and the Contour Diabetes App 2.0 on personal mobile device which communicates to meter to manage diabetes and be willing to keep a study diary

Exclusion Criteria

  • Known Hemophilia or any other bleeding disorder
  • Pregnancy (reported by subject; no pregnancy test required)
  • Current user of Contour Next One BGMS including Contour Diabetes App.
  • Physical, visual or neurological impairments that would make the person unable to perform testing with the Contour Next One BGMS or to use the Contour Diabetes App
  • Working for a competitive medical device company, or having an immediate family member or someone who is not a family member but is living within the household of someone who works for such a company.
  • Immediate family members are the subject's parents, spouse, children, and siblings, including the parent's spouse; step children and adopted children and their spouses.
  • A competitive medical device company is a company that provides a medical device or components of a device that is related to diabetes. For example, people who are not eligible are those who work for companies that create or manufacture the following (or a company that is in a partnership with a company that provides such devices): lancing devices, blood glucose monitoring systems, continuous glucose monitoring systems, insulin pens, or systems related to the measurement of HbA1c. People who are eligible are those who work for companies associated with products such as wound dressings, medications or dietary products.
  • A condition, which in the opinion of the investigator or designee, would put the person or study conduct at risk (reason for exclusion will be clearly documented by investigator or designee on the subject disposition form).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03165110). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search